Upgrade to SI Premium - Free Trial

Regeneron (REGN) Results Highlight Strong Fundamentals, Focus Remains on Novel Product Readouts - BMO Capital

February 4, 2022 3:04 PM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $780.00 price target on Regeneron Pharma (NASDAQ: REGN), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles